Diamyd Medical appoints Protein Sciences for production of its lead therapeutic diabetes vaccine
Diamyd Medical AB announced that is has reached an agreement with Protein Sciences Corporation, a biopharmaceutical service company, for production of Diamyd(TM), its lead therapeutic diabetes vaccine. Under the terms of the agreement, Protein Sciences (PSC) will produce Diamyd Medical's lead therapeutic diabetes vaccine for Phase III trials, as well as prepare to file an Investigational New Drug Application (IND) with the U.S. food & Drug Administration (FDA). Diamyd Medical also is participating in Protein Sciences' current round of financing, with a US$3 million investment.
Diamyd(TM) is based on the beta cell antigen GAD (Glutamic Acid Decarboxylase), which is produced through a Recombinant Protein Expression System consisting of baculovirus (an insect virus) and insect cells. Protein Sciences (PSC) specializes in the development of influenza vaccines and other vaccines with insect based expression systems. PSC's cell line was recently approved by the FDA for the production of recombinant vaccines produced with insect based expression systems. Hence, PSC is a logical supplier for Diamyd Medical.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.